Journal Article10.1007/S00595-013-0674-6
Intraperitoneal administration of cisplatin via an in situ cross-linkable hyaluronic acid-based hydrogel for peritoneal dissemination of gastric cancer.
Shigenobu Emoto,Hironori Yamaguchi,Takao Kamei,Hironori Ishigami,Takashi Suhara,Yukimitsu Suzuki,Taichi Ito,Joji Kitayama,Toshiaki Watanabe +8 more
65
TL;DR: In situ cross-linkable HA hydrogels represent a promising biomaterial to prolong the retention and sustain the release of intraperitoneally administered CDDP in the peritoneal cavity and to enhance its antitumor effects against peritoneAL dissemination.
read more
Abstract: To develop a drug-delivery system for the prolonged retention of intraperitoneally (i.p.) administered cisplatin (CDDP) to deliver intraperitoneal chemotherapy against peritoneal carcinomatosis effectively. CDDP was encapsulated inside an in situ cross-linkable hyaluronic acid (HA)-based hydrogel. The gelation and degradation kinetics of the hydrogel and the release kinetics of CDDP were investigated in vitro, and the antitumor effect was investigated in a mouse model of peritoneal dissemination of human gastric cancer. The gelation time varied according to the concentration of two polymers: HA-adipic dihydrazide and HA-aldehyde. CDDP was released from the hydrogel for more than 4 days. A cell proliferation assay showed that the polymers themselves were not cytotoxic toward MKN45P, a human gastric cancer cell line. By mixing the two polymers in the peritoneum, in situ gelation was achieved. The weight of peritoneal nodules decreased in the hydrogel-conjugated CDDP group, whereas no significant antitumor effect was observed in the free CDDP group. In situ cross-linkable HA hydrogels represent a promising biomaterial to prolong the retention and sustain the release of intraperitoneally administered CDDP in the peritoneal cavity and to enhance its antitumor effects against peritoneal dissemination.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Hyaluronic acid for anticancer drug and nucleic acid delivery.
TL;DR: The rationale underlying approaches, chemical strategies, and recent advances in the use of HA to design drug carriers for delivering anticancer agents, are reviewed and descriptions are given of HA-based drug conjugates, particulate carriers, inorganic nanostructures, and hydrogels.
535
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
Roopa Hariprasad,Lalit Kumar +1 more
- 01 Jan 2006
527
Polymer scaffolds as drug delivery systems
Italo Rodrigo Calori,Italo Rodrigo Calori,Gustavo Braga,Priscila da Costa Carvalho de Jesus,Hong Bi,Antonio Claudio Tedesco,Antonio Claudio Tedesco +6 more
TL;DR: This review provides an overview of all recently published studies on the development and application of polymer scaffolds targeting controlled drug delivery in medicinal fields, including regenerative medicine and cancer therapy.
223
Nanotechnology-based drug delivery systems for treatment of oral cancer: a review.
TL;DR: This study presents a systematic review of nanotechnology-based drug delivery systems for oral cancers and presents a number of promising tools for diagnostic probes and therapeutic devices.
181
Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy
Javad Sharifi-Rad,Cristina Quispe,Jayanta Kumar Patra,Yengkhom Disco Singh,Manasa Kumar Panda,Gitishree Das,Charles Oluwaseun Adetunji,Olugbenga Samuel Michael,Oksana Sytar,Oksana Sytar,Letizia Polito,Jelena Živković,Natália Cruz-Martins,Marta Klimek-Szczykutowicz,Halina Ekiert,Muhammad Iqbal Choudhary,Seyed Abdulmajid Ayatollahi,Seyed Abdulmajid Ayatollahi,Bekzat Tynybekov,Farzad Kobarfard,Ana Covilca Muntean,Ioana Grozea,Sevgi Durna Daştan,Monica Butnariu,Agnieszka Szopa,Daniela Calina +25 more
TL;DR: Paclitaxel is a broad-spectrum anticancer compound derived mainly from a medicinal plant, in particular from the bark of the yew tree Taxus brevifolia Nutt.
References
Environment-sensitive hydrogels for drug delivery
Yong Qiu,Kinam Park +1 more
TL;DR: Development of environmentally sensitive hydrogels with a wide array of desirable properties can be made is a formidable challenge, however, if the achievements of the past can be extrapolated into the future, it is highly likely that responsive hydrogelWith such properties can been made.
4.5K
Intraperitoneal cisplatin and paclitaxel in ovarian cancer
Deborah K. Armstrong,Brian N. Bundy,Lari Winzel,Helen Q. Huang,Rebecca N. Baergen,Shashikant Lele,Larry J. Copeland,Joan L. Walker,Robert A. Burger +8 more
TL;DR: Compared with the intravenous group, the intraperitoneal therapy group had significantly more grade 3 or 4 adverse events, the most severe of which were fatigue, pain, or hematologic, gastrointestinal, metabolic, or neurologic toxic effects, and there were no differences in quality of life between the two groups.
2.6K
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Deborah K. Armstrong,Brian N. Bundy,Lari Wenzel,Helen Q. Huang,Rebecca N. Baergen,Shashikant Lele,Larry J. Copeland,Joan L. Walker,Robert A. Burger +8 more
TL;DR: Quality of life was significantly worse in the intraperitoneal-therapy group before cycle 4 and three to six weeks after treatment but not one year after treatment, while survival in patients with optimally debulked stage III ovarian cancer improved.
2.5K
The ER chaperone GRP78 is associated with the severity of cerulein-induced pancreatic inflammation via regulating apoptosis of pancreatic acinar cells.
TL;DR: GRP78 expression was associated with apoptosis and the severity of cerulein-induced pancreatic inflammation, indicating that GRP78 might prevent apoptosis in pancreatic acinar cells thereby deteriorating the severityof AP.
1.9K
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Wasaburo Koizumi,H. Narahara,Takuo Hara,Akinori Takagane,Toshikazu Akiya,Masakazu Takagi,Kosei Miyashita,Takashi Nishizaki,Osamu Kobayashi,Wataru Takiyama,Yasushi Toh,Takashi Nagaie,Seiichi Takagi,Yoshitaka Yamamura,Kimihiko Yanaoka,Hiroyuki Orita,Masahiro Takeuchi +16 more
TL;DR: S-1 plus cisplatin holds promise of becoming a standard first-line treatment for patients with advanced gastric cancer, and progression-free survival was significantly longer in patients assigned to S-1plus cis Platin than in those assigned to s-1 alone.
1.7K